Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 15 (7), 1078-80

Concurrent Use of Folinic Acid and Methotrexate in Rheumatoid Arthritis

Affiliations
  • PMID: 3050087
Clinical Trial

Concurrent Use of Folinic Acid and Methotrexate in Rheumatoid Arthritis

P S Hanrahan et al. J Rheumatol.

Abstract

In a double blind placebo controlled crossover study, each arm of 4 weeks' duration, 20 mg of folinic acid/week or placebo were administered to 13 patients with rheumatoid arthritis. These individuals were receiving weekly intramuscular methotrexate (MTX) but were about to discontinue because of side effects. While there was considerable improvement in nausea during the study, the effect of folinic acid could not be differentiated from that of placebo. There was no adverse effect on control of disease activity. It therefore seems likely that polyglutamated tissue stores of MTX do not contribute to drug efficacy and in this format folinic acid could not be shown to be more useful than placebo in reducing drug induced nausea.

Similar articles

See all similar articles

Cited by 13 articles

See all "Cited by" articles

Publication types

Feedback